Stock analysis searches answered, part 28 of 43

Regentis biomaterials ltd. bullish and bearish analyst opinions

For “Regentis biomaterials ltd. bullish and bearish analyst opinions”, the matching SEC registrant is REGENTIS BIOMATERIALS LTD., which trades as RGNT and files under Central Index Key 1912966. EDGAR puts it in the “Orthopedic, Prosthetic & Surgical Appliances & Supplies” industry code with Israel as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 6-K filed 2026-10-13, across 93 filings on record. This is reference material, not trading advice.

Financial trend for REGENTIS BIOMATERIALS LTD. from annual reports, periods 2023-12-31 to 2025-12-31: net income (loss) went from -$4.13 million (2023-12-31) to -$13.65 million (2025-12-31), a change of -230.3%; total assets went from $482,000 (2024-12-31) to $7.62 million (2025-12-31), a change of +1480.5%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1912966, tags Assets, NetIncomeLoss; 3 periods shown, dashes mark figures REGENTIS BIOMATERIALS LTD. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on REGENTIS BIOMATERIALS LTD. (CIK 1912966) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 20-F annual report was filed 2026-02-24. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 19 8-K or 6-K reports in REGENTIS BIOMATERIALS LTD.’s recent EDGAR index, the 4 listed here run from 2026-07-15 to 2026-10-13, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 93 recent EDGAR filings, REGENTIS BIOMATERIALS LTD. most often filed 6-K (19), CORRESP (10), F-1/A (9), 3 (9). A selection from 2026-07-13 to 2026-09-22:

The full record for CIK 1912966 is on the EDGAR company page; the latest 20-F there is dated 2026-02-24 and the oldest filing in the recent index dates from 2022-03-29. Insider trades for REGENTIS BIOMATERIALS LTD. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Rexnord electronics and controls limited bullish and bearish analyst opinions

The legal-form ending in “Rexnord electronics and controls limited” is the clue: “Limited” is the company form used across Hong Kong, Australia, Singapore and other Commonwealth markets. A company of that kind reports in a Commonwealth jurisdiction (most often Hong Kong, Australia, Singapore or Canada), so the place to read its annual report and announcements is that market’s exchange filing system (HKEXnews, ASX announcements, SGXNet or SEDAR+) — www.hkexnews.hk.

No SEC filer could be matched to “Rexnord electronics and controls limited bullish and bearish analyst opinions” with a single, clear Central Index Key: neither EDGAR’s company index nor its full-text search (phrase “Rexnord electronics and controls limited”) returns a registrant with this name. Rather than show another company’s numbers, this section explains what the official record does and does not contain for the term “rexnord” (search terms considered: rexnord, electronics, controls).

Even the shorter phrase “Rexnord electronics controls” returns no EDGAR full-text hits, so no SEC filing since 2001 mentions it; the terms in this search (rexnord, electronics, controls) point to a business outside the SEC system or one known by another legal name.

EDGAR’s company index has 10 entities whose registered name contains the word “rexnord”; the first few are shown below so you can see whether any is the business you mean. None of them matches the full search wording closely enough to be treated as the same company.

Word by word, the number of EDGAR registrant names containing each term of this search is: “rexnord” 10, “electronics” 250, “controls” 73. A term that appears in many unrelated names is a weak identifier on its own, which is why this page does not attach any one filer’s financial data to the query.

Sample EDGAR registrant names, term by term — containing “rexnord”: REGAL REXNORD CORP (CIK 82811), REXNORD CORP (CIK 843762), REXNORD CORP (CIK 1439288); containing “electronics”: ACCUSPEC ELECTRONICS LLC (CIK 1357186), ACI ELECTRONICS LLC (CIK 1403015), ADVANCED OPTICS ELECTRONICS INC (CIK 1020657); containing “controls”: 4C CONTROLS INC (CIK 1318820), ASSURE BIOASSAY CONTROLS INC (CIK 1367702), ASSURE CONTROLS INC (CIK 1406119). These are listed only to show how the individual words map onto unrelated filers; none should be read as the subject of the search.

For this particular search: analyst views on “rexnord” are third-party opinions; the SEC neither issues nor reviews ratings, so check any rating against the company’s own annual report. If the business says it is registered but does not appear in EDGAR or on FINRA BrokerCheck, treat that as a red flag. This page offers no buy or sell recommendation.

Updated Oct 25, 2026 ET

Rre ventures acquisition corp. bullish and bearish analyst opinions

For “Rre ventures acquisition corp. bullish and bearish analyst opinions”, the matching SEC registrant is RRE Ventures Acquisition Corp., which trades as RREV, RREVU, RREVW and files under Central Index Key 2123969. EDGAR puts it in the “Blank Checks” industry code with DE as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a SCHEDULE 13G filed 2026-08-14, across 38 filings on record. This is reference material, not trading advice.

Analyst ratings, price targets and “bullish” or “bearish” calls on RRE Ventures Acquisition Corp. (CIK 2123969) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Deal and listing documents for RRE Ventures Acquisition Corp. — registration statements, prospectuses and merger proxies — are filed on EDGAR; 4 such filings (424B4, S-1, S-1/A) appear in its recent index, the newest dated 2026-05-01.

Current reports. Of the 3 8-K or 6-K reports in RRE Ventures Acquisition Corp.’s recent EDGAR index, the 3 listed here run from 2026-05-01 to 2026-05-14, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 38 recent EDGAR filings, RRE Ventures Acquisition Corp. most often filed 3 (11), 4 (7), SCHEDULE 13G (5), 8-K (3). A selection from 2026-08-12 to 2026-08-14:

The full record for CIK 2123969 is on the EDGAR company page and the oldest filing in the recent index dates from 2026-04-07. Insider trades for RRE Ventures Acquisition Corp. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Rzlv

For “Rzlv”, the matching SEC registrant is REZOLVE AI PLC, which trades as RZLV, RZLVW and files under Central Index Key 1920294. EDGAR puts it in the “Services-Computer Programming, Data Processing, Etc.” industry code with United Kingdom as its state or country of incorporation; its earlier registered name was REZOLVE AI PLC. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 6-K filed 2026-10-08, across 203 filings on record. This is reference material, not trading advice.

Financial trend for REZOLVE AI PLC from annual reports, periods 2023-12-31 to 2025-12-31: revenue went from $145,051 (2023-12-31) to $46.80 million (2025-12-31), a change of +32164.6%; net income (loss) went from -$30.74 million (2023-12-31) to -$101.41 million (2025-12-31), a change of -229.9%; total assets went from $2.54 million (2023-12-31) to $611.73 million (2025-12-31), a change of +24017.4%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1920294, tags Assets, NetIncomeLoss, RevenueFromContractWithCustomerExcludingAssessedTax; 3 periods shown, dashes mark figures REZOLVE AI PLC did not tag for that period.

REZOLVE AI PLC has 203 filings in its recent EDGAR index, including 3 annual reports and 0 quarterly reports; its newest filing is a 6-K from 2026-10-08.

Current reports. Of the 60 8-K or 6-K reports in REZOLVE AI PLC’s recent EDGAR index, the 4 listed here run from 2026-08-06 to 2026-10-08, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 203 recent EDGAR filings, REZOLVE AI PLC most often filed 6-K (60), CORRESP (21), UPLOAD (14), 424B3 (12). A selection from 2026-05-15 to 2026-08-28:

The full record for CIK 1920294 is on the EDGAR company page; the latest 20-F there is dated 2026-03-30 and the oldest filing in the recent index dates from 2023-06-16. Insider trades for REZOLVE AI PLC appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Sadot group inc. bullish and bearish analyst opinions

For “Sadot group inc. bullish and bearish analyst opinions”, the matching SEC registrant is Sadot Group Inc., which trades as SDOT and files under Central Index Key 1701756. EDGAR puts it in the “Retail-Eating & Drinking Places” industry code with NV as its state or country of incorporation; its earlier registered name was Muscle Maker, Inc. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 8-K filed 2026-10-13, across 694 filings on record. This is reference material, not trading advice.

Financial trend for Sadot Group Inc. from annual reports, periods 2022-12-31 to 2025-12-31: net income (loss) went from -$7.96 million (2022-12-31) to -$93.39 million (2025-12-31), a change of -1072.9%; total assets went from $27.23 million (2022-12-31) to $2.90 million (2025-12-31), a change of -89.4%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1701756, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures Sadot Group Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Sadot Group Inc. (CIK 1701756) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-14, and the most recent 10-K annual report was filed 2026-04-29. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 180 8-K or 6-K reports in Sadot Group Inc.’s recent EDGAR index, the 4 listed here run from 2026-09-25 to 2026-10-13, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1701756 is on the EDGAR company page; the latest 10-K there is dated 2026-04-29 and the oldest filing in the recent index dates from 2017-03-30. Insider trades for Sadot Group Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Sandy holdco b.v. filings debt

Read from its name, “Sandy holdco b.v. filings debt” is a the Netherlands entity — “N.V.” and “B.V.” are Dutch public and private limited company forms. Its accounts and exchange notices are published through the Dutch AFM registers and the KvK commercial register (www.afm.nl); the SEC only receives filings from such a company if it sells registered securities in the U.S.

No SEC filer could be matched to “Sandy holdco b.v. filings debt” with a single, clear Central Index Key: neither EDGAR’s company index nor its full-text search (phrase “Sandy holdco b.v. filings debt”) returns a registrant with this name. Rather than show another company’s numbers, this section explains what the official record does and does not contain for the term “sandy” (search terms considered: sandy, holdco, filings, debt).

Even the shorter phrase “Sandy holdco b.v.” returns no EDGAR full-text hits, so no SEC filing since 2001 mentions it; the terms in this search (sandy, holdco, filings, debt) point to a business outside the SEC system or one known by another legal name.

EDGAR’s company index has 92 entities whose registered name contains the word “sandy”; the first few are shown below so you can see whether any is the business you mean. None of them matches the full search wording closely enough to be treated as the same company.

Word by word, the number of EDGAR registrant names containing each term of this search is: “sandy” 92, “holdco” 493, “filings” 6, “debt” 490. A term that appears in many unrelated names is a weak identifier on its own, which is why this page does not attach any one filer’s financial data to the query.

Sample EDGAR registrant names, term by term — containing “sandy”: BEALL SANDY (CIK 1820218), BIG SANDY 2003 LTD (CIK 1231322), BIG SANDY 2014 (CIK 1595019); containing “holdco”: 100 EAST HOLDCO, LLC (CIK 1993765), 11321 WOODMEADOW HOLDCO, LLC (CIK 2064284), 13822 SOUTH 46TH PLACE HOLDCO, LLC (CIK 1764035); containing “filings”: BACCHUS FILINGS INC. (CIK 1415408), ON TIME FILINGS, INC. (CIK 1483935), SECURITAS EDGAR FILINGS, INC. (CIK 1456857); containing “debt”: 1903 DEBT FUND LP (CIK 1381304), 1903 OFFSHORE DEBT FUND LTD (CIK 1386324), A-A EUROPEAN SENIOR DEBT FUND, L.P. (CIK 1531061). These are listed only to show how the individual words map onto unrelated filers; none should be read as the subject of the search.

For this particular search: if “sandy” is a brand or product, the listed parent may file under a different name, so search the parent’s legal name in EDGAR company search. If the business says it is registered but does not appear in EDGAR or on FINRA BrokerCheck, treat that as a red flag. This page offers no buy or sell recommendation.

Updated Oct 25, 2026 ET

Satellos bioscience inc. bullish and bearish analyst opinions

For “Satellos bioscience inc. bullish and bearish analyst opinions”, the matching SEC registrant is Satellos Bioscience Inc., which trades as MSLE and files under Central Index Key 1421642. EDGAR puts it in the “Pharmaceutical Preparations” industry code with Canada (Federal Level) as its state or country of incorporation; its earlier registered name was ICO THERAPEUTICS INC. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 6-K filed 2026-10-21, across 52 filings on record. This is reference material, not trading advice.

Financial trend for Satellos Bioscience Inc. from annual reports, periods 2023-12-31 to 2024-12-31: net income (loss) was tagged only for 2024-12-31 at -28,099,000 CAD; total assets went from 44,298,000 CAD (2023-12-31) to 73,017,000 CAD (2024-12-31), a change of +64.8%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1421642, tags Assets, ProfitLoss; 2 periods shown, dashes mark figures Satellos Bioscience Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Satellos Bioscience Inc. (CIK 1421642) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 40-F annual report was filed 2026-03-27. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 28 8-K or 6-K reports in Satellos Bioscience Inc.’s recent EDGAR index, the 4 listed here run from 2026-09-24 to 2026-10-21, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 52 recent EDGAR filings, Satellos Bioscience Inc. most often filed 6-K (28), D (8), SUPPL (2), F-X (2). A selection from 2026-05-12 to 2026-08-14:

The full record for CIK 1421642 is on the EDGAR company page; the latest 40-F there is dated 2026-03-27 and the oldest filing in the recent index dates from 2007-12-17. Insider trades for Satellos Bioscience Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Scinai immunotherapeutics ltd. bullish and bearish analyst opinions

For “Scinai immunotherapeutics ltd. bullish and bearish analyst opinions”, the matching SEC registrant is Scinai Immunotherapeutics Ltd., which trades as SCNI and files under Central Index Key 1611747. EDGAR puts it in the “Biological Products, (No Diagnostic Substances)” industry code with Israel as its state or country of incorporation; its earlier registered name was BiondVax Pharmaceuticals Ltd. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 6-K filed 2026-10-20, across 494 filings on record. This is reference material, not trading advice.

Financial trend for Scinai Immunotherapeutics Ltd. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $658,000 (2024-12-31) to $1.31 million (2025-12-31), a change of +99.2%; net income (loss) went from -$5.80 million (2022-12-31) to -$8.31 million (2025-12-31), a change of -43.3%; total assets went from $27.07 million (2022-12-31) to $11.63 million (2025-12-31), a change of -57.0%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1611747, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures Scinai Immunotherapeutics Ltd. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Scinai Immunotherapeutics Ltd. (CIK 1611747) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 20-F annual report was filed 2026-04-01. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 285 8-K or 6-K reports in Scinai Immunotherapeutics Ltd.’s recent EDGAR index, the 4 listed here run from 2026-10-13 to 2026-10-20, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 494 recent EDGAR filings, Scinai Immunotherapeutics Ltd. most often filed 6-K (281), CORRESP (26), 3 (20), EFFECT (19). A selection from 2026-07-09 to 2026-10-05:

The full record for CIK 1611747 is on the EDGAR company page; the latest 20-F there is dated 2026-04-01 and the oldest filing in the recent index dates from 2014-11-13. Insider trades for Scinai Immunotherapeutics Ltd. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Semileds corporation bullish and bearish analyst opinions

For “Semileds corporation bullish and bearish analyst opinions”, the matching SEC registrant is SemiLEDs Corp, which trades as LEDS and files under Central Index Key 1333822. EDGAR puts it in the “Semiconductors & Related Devices” industry code with an unstated jurisdiction as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 8-K filed 2026-08-31, across 487 filings on record. This is reference material, not trading advice.

Financial trend for SemiLEDs Corp from annual reports, periods 2022-08-31 to 2025-08-31: revenue went from $7.05 million (2022-08-31) to $43.01 million (2025-08-31), a change of +510.0%; net income (loss) went from -$2.74 million (2022-08-31) to -$1.13 million (2025-08-31), a change of +58.8%; total assets went from $16.05 million (2022-08-31) to $15.59 million (2025-08-31), a change of -2.9%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1333822, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures SemiLEDs Corp did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on SemiLEDs Corp (CIK 1333822) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-07-14, and the most recent 10-K annual report was filed 2025-11-28. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 139 8-K or 6-K reports in SemiLEDs Corp’s recent EDGAR index, the 4 listed here run from 2026-07-14 to 2026-08-31, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 487 recent EDGAR filings, SemiLEDs Corp most often filed 8-K (139), 4 (110), 10-Q (48), 3 (25). A selection from 2026-07-14 to 2026-07-15:

The full record for CIK 1333822 is on the EDGAR company page; the latest 10-K there is dated 2025-11-28 and the oldest filing in the recent index dates from 2005-03-30. Insider trades for SemiLEDs Corp appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Senti biosciences, inc. bullish and bearish analyst opinions

For “Senti biosciences, inc. bullish and bearish analyst opinions”, the matching SEC registrant is Senti Biosciences Holdings, Inc., which trades as SNTI and files under Central Index Key 1854270. EDGAR puts it in the “Biological Products, (No Diagnostic Substances)” industry code with DE as its state or country of incorporation; its earlier registered name was Senti Biosciences, Inc. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 4 filed 2026-10-23, across 365 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-03-27 by Senti Biosciences Holdings, Inc. (CIK 1854270) — source document:

Unless the context otherwise requires, for purposes of this section, the terms “we,” “us,” “our,” “our Company,” “the Company” or “Senti” refer to Senti Biosciences, Inc. and its subsidiaries. Overview We are a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with our gene circuit platform technologies for patients living with incurable diseases. Our mission is to create a new generation of smarter medicines that outsmart complex diseases using novel and unprecedented approaches. To accomplish this mission, we have built a synthetic biology platform that we believe may enable us to program next-generation cell and gene therapies with gene circuits. These gene circuits, which we created from novel and proprietary combinations of DNA sequences, are designed to reprogram cells with biological logic to sense inputs, compute decisions and respond to their respective cellular environments.

Financial trend for Senti Biosciences Holdings, Inc. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $4.29 million (2022-12-31) to $0 (2024-12-31), a change of -100.0%; net income (loss) went from -$58.21 million (2022-12-31) to -$61.44 million (2025-12-31), a change of -5.5%; total assets went from $180.79 million (2022-12-31) to $51.22 million (2025-12-31), a change of -71.7%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1854270, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures Senti Biosciences Holdings, Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Senti Biosciences Holdings, Inc. (CIK 1854270) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-07-15, and the most recent 10-K annual report was filed 2026-03-27. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 76 8-K or 6-K reports in Senti Biosciences Holdings, Inc.’s recent EDGAR index, the 4 listed here run from 2026-09-04 to 2026-10-15, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1854270 is on the EDGAR company page; the latest 10-K/A there is dated 2026-04-29 and the oldest filing in the recent index dates from 2021-04-02. Insider trades for Senti Biosciences Holdings, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Sera prognostics

For “Sera prognostics”, the matching SEC registrant is SERA PROGNOSTICS, INC., which trades as SERA and files under Central Index Key 1534969. EDGAR puts it in the “Services-Medical Laboratories” industry code with DE as its state or country of incorporation; its earlier registered name was SERA PROGNOSTICS, INC. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 4 filed 2026-10-13, across 658 filings on record. This is reference material, not trading advice.

Financial trend for SERA PROGNOSTICS, INC. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $306,000 (2023-12-31) to $81,000 (2025-12-31), a change of -73.5%; net income (loss) went from -$44.19 million (2022-12-31) to -$31.93 million (2025-12-31), a change of +27.7%; total assets went from $116.33 million (2022-12-31) to $101.93 million (2025-12-31), a change of -12.4%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1534969, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures SERA PROGNOSTICS, INC. did not tag for that period.

SERA PROGNOSTICS, INC. has 658 filings in its recent EDGAR index, including 5 annual reports and 16 quarterly reports; its newest filing is a 4 from 2026-10-13.

Current reports. Of the 52 8-K or 6-K reports in SERA PROGNOSTICS, INC.’s recent EDGAR index, the 4 listed here run from 2026-06-04 to 2026-08-19, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 658 recent EDGAR filings, SERA PROGNOSTICS, INC. most often filed 4 (283), 144 (177), 8-K (52), 3 (28). A selection from 2026-09-11 to 2026-10-13:

The full record for CIK 1534969 is on the EDGAR company page; the latest 10-K there is dated 2026-03-18 and the oldest filing in the recent index dates from 2011-11-21. Insider trades for SERA PROGNOSTICS, INC. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Serina therapeutics, inc. bullish and bearish analyst opinions

For “Serina therapeutics, inc. bullish and bearish analyst opinions”, the matching SEC registrant is Serina Therapeutics, Inc., which trades as SER and files under Central Index Key 1708599. EDGAR puts it in the “Pharmaceutical Preparations” industry code with AL as its state or country of incorporation; its earlier registered name was AgeX Therapeutics, Inc. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 8-K filed 2026-10-09, across 518 filings on record. This is reference material, not trading advice.

Financial trend for Serina Therapeutics, Inc. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $34,000 (2022-12-31) to $130,000 (2025-12-31), a change of +282.4%; net income (loss) went from -$10.46 million (2022-12-31) to -$19.18 million (2025-12-31), a change of -83.3%; total assets went from $3.24 million (2022-12-31) to $6.95 million (2025-12-31), a change of +114.5%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1708599, tags Assets, NetIncomeLoss, RevenueFromContractWithCustomerExcludingAssessedTax; 4 periods shown, dashes mark figures Serina Therapeutics, Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Serina Therapeutics, Inc. (CIK 1708599) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-13, and the most recent 10-K annual report was filed 2026-03-25. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 153 8-K or 6-K reports in Serina Therapeutics, Inc.’s recent EDGAR index, the 4 listed here run from 2026-08-13 to 2026-10-09, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 518 recent EDGAR filings, Serina Therapeutics, Inc. most often filed 8-K (153), 4 (143), SC 13D/A (36), 3 (29). A selection from 2026-07-23 to 2026-08-31:

The full record for CIK 1708599 is on the EDGAR company page; the latest 10-K/A there is dated 2026-03-27 and the oldest filing in the recent index dates from 2017-07-10. Insider trades for Serina Therapeutics, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Sizzle acquisition corp. ii bullish and bearish analyst opinions

For “Sizzle acquisition corp. ii bullish and bearish analyst opinions”, the matching SEC registrant is Sizzle Acquisition Corp. II, which trades as SZZL, SZZLR, SZZLU and files under Central Index Key 2030663. EDGAR puts it in the “Blank Checks” industry code with Cayman Islands as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 425 filed 2026-10-13 (this view begins at filings dated on or before 2026-08-25), across 62 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-03-12 by Sizzle Acquisition Corp. II (CIK 2030663) (passage 2, continuing from the earlier excerpt) — source document:

These industries complement our Management Team’s and Board’s extensive background, and we seek to capitalize on the ability of our Management Team to identify and acquire a target business in such sectors. We are focusing our initial Business Combination efforts on targets that (i) have strong brand and business fundamentals; (ii) have a definable path forward; (iii) will benefit from our Management Team’s or Board’s expertise in creating, building, marketing, distributing, leading and monetizing brands and products; (iv) will likely benefit from enhanced data gathering; and (v) can serve as a platform company to make future acquisitions. As of the date of this Report, our efforts have been limited to (i) organizational activities, (ii) activities related to our Initial Public Offering, and (iii) searching for and consummating a Business Combination; we have not selected any specific Business Combination target.

Financial trend for Sizzle Acquisition Corp. II from quarterly and annual reports (three-month periods), periods 2025-09-30 to 2026-06-30: net income (loss) went from $2.29 million (2025-09-30) to $1.82 million (2026-06-30), a change of -20.5%; total assets went from $235.83 million (2025-09-30) to $241.66 million (2026-06-30), a change of +2.5%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 2030663, tags Assets, NetIncomeLoss; 3 periods shown, dashes mark figures Sizzle Acquisition Corp. II did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Sizzle Acquisition Corp. II (CIK 2030663) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 10-K annual report was filed 2026-03-12. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Deal and listing documents for Sizzle Acquisition Corp. II — registration statements, prospectuses and merger proxies — are filed on EDGAR; 15 such filings (424B3, 425, S-1, S-1/A) appear in its recent index, the newest dated 2026-10-13.

Current reports. Of the 9 8-K or 6-K reports in Sizzle Acquisition Corp. II’s recent EDGAR index, the 4 listed here run from 2025-04-09 to 2026-04-17, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 2030663 is on the EDGAR company page; the latest 10-K there is dated 2026-03-12 and the oldest filing in the recent index dates from 2024-08-28. One example from this record is the 425 filed 2026-10-07 (document). Insider trades for Sizzle Acquisition Corp. II appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Somnigroup international sgi news october 2026

For “Somnigroup international sgi news october 2026”, the matching SEC registrant is SOMNIGROUP INTERNATIONAL INC., which trades as SGI and files under Central Index Key 1206264. EDGAR puts it in the “Household Furniture” industry code with DE as its state or country of incorporation; its earlier registered name was TEMPUR SEALY INTERNATIONAL, INC. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a S-8 filed 2026-09-08, across 1002 filings on record. This is reference material, not trading advice.

On February 5, 2025, we completed the previously announced acquisition of Mattress Firm, the nation's largest mattress specialty retailer. The total purchase price was approximately $5.1 billion, net of cash acquired of $0.3 billion. The aggregate purchase price consisted of $3.1 billion in cash and approximately 34.2 million shares of common stock valued at $65.65 per share, which represents the simple average of the opening and closing price per share of our common stock on the NYSE on the trading day immediately prior to the date of acquisition, with the value of any fractional shares paid in cash. In connection with the closing of the Mattress Firm Acquisition, we amended our Certificate of Incorporation to change our name to "Somnigroup International Inc." effective February 18, 2025.

Updated Oct 25, 2026 ET

Soulpower acquisition corporation

For “Soulpower acquisition corporation”, the matching SEC registrant is Soulpower Acquisition Corp., which trades as SOUL, SOUL-RI, SOUL-UN and files under Central Index Key 2025608. EDGAR puts it in the “Blank Checks” industry code with Cayman Islands as its state or country of incorporation; its earlier registered name was Soulpower Acquisition Corp. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 425 filed 2026-09-03, across 77 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-03-27 by Soulpower Acquisition Corp. (CIK 2025608) — source document:

Our shareholders can also vote at any time to amend our amended and restated memorandum and articles of association to modify the amount of time we will have to complete an initial business combination, in which case our public shareholders; ● “founder shares” are to Class B ordinary shares initially purchased by our sponsor in a private placement prior to our initial public offering and the Class A ordinary shares that will be issued upon the automatic conversion of the Class B ordinary shares at the time of our initial business combination or earlier at the option of the holders thereof as described herein (for the avoidance of doubt, such Class A ordinary shares will not be “public shares”); ● “initial shareholders” are to our sponsor and any other holders of our founder shares immediately prior to our initial public offering; ● “Investment Company Act” are to the Investment Company Act of 1940, as amended; ● “management” or our “management team” are to our officers and directors; ● “ordinary resolution” are to a resolution of the company passed by a simple majority of the votes cast by such shareholders as,

Financial trend for Soulpower Acquisition Corp. from annual reports, periods 2024-12-31 to 2025-12-31: net income (loss) was tagged only for 2025-12-31 at $5.96 million; total assets went from $100,548 (2024-12-31) to $259.13 million (2025-12-31), a change of +257613.2%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 2025608, tags Assets, NetIncomeLoss; 2 periods shown, dashes mark figures Soulpower Acquisition Corp. did not tag for that period.

Deal and listing documents for Soulpower Acquisition Corp. — registration statements, prospectuses and merger proxies — are filed on EDGAR; 11 such filings (424B4, 425, S-1, S-1/A, S-1MEF) appear in its recent index, the newest dated 2026-09-03.

Current reports. Of the 14 8-K or 6-K reports in Soulpower Acquisition Corp.’s recent EDGAR index, the 4 listed here run from 2026-04-06 to 2026-09-03, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 2025608 is on the EDGAR company page; the latest 10-K there is dated 2026-03-27 and the oldest filing in the recent index dates from 2024-08-14. Insider trades for Soulpower Acquisition Corp. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Soulpower acquisition corporation bullish and bearish analyst opinions

For “Soulpower acquisition corporation bullish and bearish analyst opinions”, the matching SEC registrant is Soulpower Acquisition Corp., which trades as SOUL, SOUL-RI, SOUL-UN and files under Central Index Key 2025608. EDGAR puts it in the “Blank Checks” industry code with Cayman Islands as its state or country of incorporation; its earlier registered name was Soulpower Acquisition Corp. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 425 filed 2026-09-03 (this view begins at filings dated on or before 2026-04-06), across 77 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-03-27 by Soulpower Acquisition Corp. (CIK 2025608) (passage 2, continuing from the earlier excerpt) — source document:

Financial trend for Soulpower Acquisition Corp. from quarterly and annual reports (three-month periods), periods 2025-09-30 to 2026-06-30: net income (loss) went from $2.24 million (2025-09-30) to $1.92 million (2026-06-30), a change of -14.2%; total assets went from $255.73 million (2025-09-30) to $265.32 million (2026-06-30), a change of +3.7%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 2025608, tags Assets, NetIncomeLoss; 3 periods shown, dashes mark figures Soulpower Acquisition Corp. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Soulpower Acquisition Corp. (CIK 2025608) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 10-K annual report was filed 2026-03-27. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 14 8-K or 6-K reports in Soulpower Acquisition Corp.’s recent EDGAR index, the 4 listed here run from 2025-12-30 to 2026-03-31, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 2025608 is on the EDGAR company page; the latest 10-K there is dated 2026-03-27 and the oldest filing in the recent index dates from 2024-08-14. One example from this record is the 8-K filed 2026-07-30 (document). Insider trades for Soulpower Acquisition Corp. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Star holdings stho latest news

For “Star holdings stho latest news”, the matching SEC registrant is Star Holdings, which trades as STHO and files under Central Index Key 1953366. EDGAR puts it in the “Lessors of Real Property, NEC” industry code with MD as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 8-K filed 2026-10-09, across 113 filings on record. This is reference material, not trading advice.

Following the Spin-Off, we became an independent, publicly traded company. Our common shares commenced regular-way trading on the Nasdaq Global Market (the “Nasdaq”) under the symbol “STHO” on March 31, 2023. We are externally managed by a wholly-owned subsidiary of Safe (the “Manager”). In connection with the Spin-Off, the Company entered into the Separation and Distribution Agreement, a management agreement with the Manager (the "Management Agreement"), a governance agreement with Safe (the "Governance Agreement") and a registration rights agreement with Safe (the "Registration Rights Agreement"). Since the date of the Spin-Off, certain of the legacy real estate assets have been sold or repaid. Additional information on our portfolio as of December 31, 2025 is set forth below. ​ Our Development Portfolio ​ Asbury Park Waterfront ​ We are the managing member in Asbury Partners, LLC, which is the joint venture that owns the Asbury Park Waterfront investment.

Updated Oct 25, 2026 ET

Stereotaxis, inc. bullish and bearish analyst opinions

For “Stereotaxis, inc. bullish and bearish analyst opinions”, the matching SEC registrant is Stereotaxis, Inc., which trades as STXS and files under Central Index Key 1289340. EDGAR puts it in the “Electromedical & Electrotherapeutic Apparatus” industry code with DE as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a SCHEDULE 13G filed 2026-08-19, across 1003 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-03-12 by Stereotaxis, Inc. (CIK 1289340) — source document:

In this report, “Stereotaxis”, the “Company”, “Registrant”, “we”, “us”, and “our” refer to Stereotaxis, Inc. and its wholly owned subsidiaries. GenesisX RMN ® , Genesis RMN ® , Niobe ® , Navigant ® , Synchrony™, SynX™, Odyssey ® , Odyssey Cinema ™ , MAGiC™, MAGiC Sweep™, EMAGIN™, Map-iT™, QuikCAS ™, Cardiodrive ® , Vdrive ® , Vdrive Duo ™ , V-CAS ™ , V-Loop ™ , V-Sono™, and NuVizion™ are trademarks of Stereotaxis, Inc. All other trademarks that appear in this report are the property of their respective owners.

Financial trend for Stereotaxis, Inc. from annual reports, periods 2022-12-31 to 2025-12-31: net income (loss) went from -$18.29 million (2022-12-31) to -$21.64 million (2025-12-31), a change of -18.3%; total assets went from $53.41 million (2022-12-31) to $52.25 million (2025-12-31), a change of -2.2%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1289340, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures Stereotaxis, Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Stereotaxis, Inc. (CIK 1289340) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-11, and the most recent 10-K annual report was filed 2026-03-12. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 171 8-K or 6-K reports in Stereotaxis, Inc.’s recent EDGAR index, the 4 listed here run from 2026-05-15 to 2026-08-11, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1289340 is on the EDGAR company page; the latest 10-K/A there is dated 2026-04-03 and the oldest filing in the recent index dates from 2011-01-04. Insider trades for Stereotaxis, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Suncar technology group inc. bullish and bearish analyst opinions

For “Suncar technology group inc. bullish and bearish analyst opinions”, the matching SEC registrant is SunCar Technology Group Inc., which trades as SDA, SDAWW and files under Central Index Key 1936804. EDGAR puts it in the “Services-Automotive Repair, Services & Parking” industry code with Cayman Islands as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 6-K filed 2026-09-22, across 112 filings on record. This is reference material, not trading advice.

Business description, quoted from the 20-F filed 2026-04-28 by SunCar Technology Group Inc. (CIK 1936804) — source document:

The mailing address of the Company’s principal executive office is Suite 209, No. 656 Lingshi Road, Jing’an District, Shanghai, 200072, People’s Republic of China, and its telephone number is (86) 138-1779-6110. The Company is subject to certain of the informational filing requirements of the Exchange Act. Since the Company is a “foreign private issuer,” the officers, directors and principal shareholders of the Company are exempt from the reporting and “short-swing” profit recovery provisions contained in Section 16 of the Exchange Act with respect to their purchase and sale of Class A Ordinary Shares. In addition, the Company is not required to file reports and financial statements with the SEC as frequently or as promptly as U.S. public companies whose securities are registered under the Exchange Act.

Financial trend for SunCar Technology Group Inc. from annual reports, periods 2021-12-31 to 2024-12-31: revenue went from $249.24 million (2021-12-31) to $441.90 million (2024-12-31), a change of +77.3%; net income (loss) went from -$18.09 million (2021-12-31) to -$64.45 million (2024-12-31), a change of -256.3%; total assets went from $191.97 million (2022-12-31) to $246.73 million (2024-12-31), a change of +28.5%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1936804, tags Assets, ProfitLoss, Revenues; 4 periods shown, dashes mark figures SunCar Technology Group Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on SunCar Technology Group Inc. (CIK 1936804) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 20-F annual report was filed 2026-04-28. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 26 8-K or 6-K reports in SunCar Technology Group Inc.’s recent EDGAR index, the 4 listed here run from 2026-05-27 to 2026-09-22, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1936804 is on the EDGAR company page; the latest 20-F there is dated 2026-04-28 and the oldest filing in the recent index dates from 2022-07-08. Insider trades for SunCar Technology Group Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Swarmer, inc common stock bullish and bearish analyst opinions

For “Swarmer, inc common stock bullish and bearish analyst opinions”, the matching SEC registrant is Swarmer, Inc, which trades as SWMR and files under Central Index Key 2092574. EDGAR puts it in the “Services-Prepackaged Software” industry code with DE as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 4 filed 2026-10-20, across 79 filings on record. This is reference material, not trading advice.

Financial trend for Swarmer, Inc from quarterly and annual reports (three-month periods), periods 2025-06-30 to 2026-06-30: revenue went from $138,206 (2025-06-30) to $216,413 (2026-06-30), a change of +56.6%; net income (loss) went from -$1.63 million (2025-06-30) to -$7.33 million (2026-06-30), a change of -350.2%; total assets went from $24.93 million (2026-03-31) to $33.94 million (2026-06-30), a change of +36.1%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 2092574, tags Assets, NetIncomeLoss, Revenues; 3 periods shown, dashes mark figures Swarmer, Inc did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Swarmer, Inc (CIK 2092574) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-13. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 11 8-K or 6-K reports in Swarmer, Inc’s recent EDGAR index, the 4 listed here run from 2026-08-13 to 2026-09-10, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 79 recent EDGAR filings, Swarmer, Inc most often filed 4 (22), 3 (12), 8-K (11), EFFECT (3). A selection from 2026-10-02 to 2026-10-20:

The full record for CIK 2092574 is on the EDGAR company page and the oldest filing in the recent index dates from 2025-10-31. Insider trades for Swarmer, Inc appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Syna clothing limited outlook

Also searched as: syna clothing limited outlook -site:x.com -site:twitter.com -site:facebook.com -site:instagram.com -site:tiktok.com -site:youtube.com -site:linkedin.com

Read from its name, “Syna clothing limited” is a a Commonwealth jurisdiction (most often Hong Kong, Australia, Singapore or Canada) entity — “Limited” is the company form used across Hong Kong, Australia, Singapore and other Commonwealth markets. Its accounts and exchange notices are published through that market’s exchange filing system (HKEXnews, ASX announcements, SGXNet or SEDAR+) (www.hkexnews.hk); the SEC only receives filings from such a company if it sells registered securities in the U.S.

No SEC filer could be matched to “Syna clothing limited outlook” with a single, clear Central Index Key: neither EDGAR’s company index nor its full-text search (phrase “Syna clothing limited”) returns a registrant with this name. Rather than show another company’s numbers, this section explains what the official record does and does not contain for the term “syna” (search terms considered: syna, clothing, outlook).

EDGAR’s company index has 0 entities whose registered name contains the word “syna”, so the business is most likely not registered with the SEC under that name.

Word by word, the number of EDGAR registrant names containing each term of this search is: “syna” 0, “clothing” 48, “outlook” 29. A term that appears in many unrelated names is a weak identifier on its own, which is why this page does not attach any one filer’s financial data to the query.

Sample EDGAR registrant names, term by term — containing “clothing”: ABS CLOTHING COLLECTION INC (CIK 1257334), BANCHRACH CLOTHING HOLDING CORP (CIK 1320073), BAOBAB CLOTHING INC (CIK 1827319); containing “outlook”: CENTURY AT OUTLOOK, LLC (CIK 1627734), CLIENT OUTLOOK INC. (CIK 1531146), EC OUTLOOK INC (CIK 1170030). These are listed only to show how the individual words map onto unrelated filers; none should be read as the subject of the search.

For this particular search: analyst views on “syna” are third-party opinions; the SEC neither issues nor reviews ratings, so check any rating against the company’s own annual report. If the business says it is registered but does not appear in EDGAR or on FINRA BrokerCheck, treat that as a red flag. This page offers no buy or sell recommendation.

Updated Oct 25, 2026 ET

Taiwan pelican express co., ltd. bullish and bearish analyst opinions

“Co., Ltd.” is the English rendering used by limited companies across East Asia. The name “Taiwan pelican express co., ltd.” therefore points to a company organised in China, Taiwan, Korea or Japan, and its official disclosures are on the home-exchange disclosure system (SSE/SZSE in mainland China, MOPS in Taiwan, DART in Korea, EDINET in Japan) (mops.twse.com.tw), not on EDGAR.

No SEC filer could be matched to “Taiwan pelican express co., ltd. bullish and bearish analyst opinions” with a single, clear Central Index Key: the phrase “Taiwan pelican express co., ltd.” appears in 460+ EDGAR full-text search results, but those hits do not point to one clearly identifiable issuer with its own CIK. Rather than show another company’s numbers, this section explains what the official record does and does not contain for the term “taiwan” (search terms considered: taiwan, pelican, express).

A broader EDGAR full-text search for the shorter phrase “Taiwan pelican express” finds 461+ filing documents; among the top 100, the filers mentioning it most are DFA INVESTMENT DIMENSIONS GROUP INC (CIK 0000355437) (69); DFA INVESTMENT TRUST CO (CIK 0000896162) (28); Ashmore Funds (CIK 0001498498) (3). Those are documents that name the term, not proof that any of these filers is the business in the search.

In the 100 most relevant full-text hits returned for “Taiwan pelican express co., ltd.”, filings range from 2014-03-28 to 2023-12-20. The filers whose documents mention it most often are DFA INVESTMENT DIMENSIONS GROUP INC (CIK 0000355437) (69 hits); DFA INVESTMENT TRUST CO (CIK 0000896162) (28 hits); Ashmore Funds (CIK 0001498498) (3 hits). A mention in another company’s filing — as a customer, supplier, lender, fund holding or deal counterparty — does not make that filer the company you searched for.

EDGAR’s company index has 40 entities whose registered name contains the word “taiwan”; the first few are shown below so you can see whether any is the business you mean. None of them matches the full search wording closely enough to be treated as the same company.

Word by word, the number of EDGAR registrant names containing each term of this search is: “taiwan” 40, “pelican” 79, “express” 354. A term that appears in many unrelated names is a weak identifier on its own, which is why this page does not attach any one filer’s financial data to the query.

For this particular search: analyst views on “taiwan” are third-party opinions; the SEC neither issues nor reviews ratings, so check any rating against the company’s own annual report. If the business says it is registered but does not appear in EDGAR or on FINRA BrokerCheck, treat that as a red flag. This page offers no buy or sell recommendation.

Updated Oct 25, 2026 ET

Therapeuticsmd, inc. bullish and bearish analyst opinions

For “Therapeuticsmd, inc. bullish and bearish analyst opinions”, the matching SEC registrant is TherapeuticsMD, Inc., which trades as TXMD and files under Central Index Key 25743. EDGAR puts it in the “Pharmaceutical Preparations” industry code with NV as its state or country of incorporation; its earlier registered name was AMHN, Inc. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 10-Q filed 2026-08-11, across 1000 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-03-30 by TherapeuticsMD, Inc. (CIK 25743) — source document:

Throughout this Annual Report on Form 10-K (“2025 10-K Report”), the terms “we,” “us,” “our,” “TherapeuticsMD,” “the Company,” or “our company” refer to TherapeuticsMD, Inc., a Nevada corporation, and unless specified otherwise, include our wholly owned subsidiaries vitaMedMD, LLC, a Delaware limited liability company (“vitaMed”), and BocaGreenMD, Inc., a Nevada corporation (“BocaGreen”). TherapeuticsMD is a pharmaceutical royalty company that owns or has rights to trademarks, service marks, or trade names that were previously used in connection with the operation of its business, or are now licensed by another party, including TherapeuticsMD®, vitaMedMD®, BocaGreenMD®, BIJUVA®, and IMVEXXY®, which are protected under applicable intellectual property laws and are the property of the Company.

Financial trend for TherapeuticsMD, Inc. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $69.96 million (2022-12-31) to $1.76 million (2024-12-31), a change of -97.5%; net income (loss) went from $112.00 million (2022-12-31) to -$569,000 (2025-12-31), a change of -100.5%; total assets went from $90.46 million (2022-12-31) to $37.66 million (2025-12-31), a change of -58.4%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 25743, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures TherapeuticsMD, Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on TherapeuticsMD, Inc. (CIK 25743) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-11, and the most recent 10-K annual report was filed 2026-03-30. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 249 8-K or 6-K reports in TherapeuticsMD, Inc.’s recent EDGAR index, the 4 listed here run from 2026-01-21 to 2026-08-11, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 25743 is on the EDGAR company page; the latest 10-K/A there is dated 2026-04-01 and the oldest filing in the recent index dates from 2008-06-23. Insider trades for TherapeuticsMD, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Tianci international, inc. bullish and bearish analyst opinions

For “Tianci international, inc. bullish and bearish analyst opinions”, the matching SEC registrant is Tianci International, Inc., which trades as CIIT and files under Central Index Key 1557798. EDGAR puts it in the “Computer Communications Equipment” industry code with NV as its state or country of incorporation; its earlier registered name was Steampunk Wizards, Inc. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 8-K filed 2026-10-15, across 211 filings on record. This is reference material, not trading advice.

Financial trend for Tianci International, Inc. from annual reports, periods 2022-07-31 to 2025-07-31: revenue went from $752,839 (2022-07-31) to $9.28 million (2025-07-31), a change of +1133.1%; net income (loss) went from $144,149 (2022-07-31) to -$2.64 million (2025-07-31), a change of -1932.0%; total assets went from $760,339 (2022-07-31) to $3.15 million (2025-07-31), a change of +313.8%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1557798, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures Tianci International, Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Tianci International, Inc. (CIK 1557798) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-06-22, and the most recent 10-K annual report was filed 2025-10-03. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 54 8-K or 6-K reports in Tianci International, Inc.’s recent EDGAR index, the 4 listed here run from 2026-09-09 to 2026-10-15, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 211 recent EDGAR filings, Tianci International, Inc. most often filed 8-K (54), 10-Q (42), 3 (16), 10-K (13). A selection from 2026-07-22 to 2026-08-26:

The full record for CIK 1557798 is on the EDGAR company page; the latest 10-K there is dated 2025-10-03 and the oldest filing in the recent index dates from 2012-09-24. Insider trades for Tianci International, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Ticketplus ltd. bullish and bearish analyst opinions

For “Ticketplus ltd. bullish and bearish analyst opinions”, the matching SEC registrant is Ticketplus Ltd., which trades as TP and files under Central Index Key 2104296. EDGAR puts it in the “Services-Miscellaneous Amusement & Recreation” industry code with Cayman Islands as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a SCHEDULE 13G filed 2026-10-01, across 37 filings on record. This is reference material, not trading advice.

Analyst ratings, price targets and “bullish” or “bearish” calls on Ticketplus Ltd. (CIK 2104296) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 5 8-K or 6-K reports in Ticketplus Ltd.’s recent EDGAR index, the 4 listed here run from 2026-08-12 to 2026-10-01, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 37 recent EDGAR filings, Ticketplus Ltd. most often filed 3 (6), 6-K (5), F-1/A (5), 4 (4). A selection from 2026-08-10 to 2026-10-01:

The full record for CIK 2104296 is on the EDGAR company page and the oldest filing in the recent index dates from 2026-01-07. Insider trades for Ticketplus Ltd. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Tiptree inc. bullish and bearish analyst opinions

For “Tiptree inc. bullish and bearish analyst opinions”, the matching SEC registrant is TIPTREE INC., which trades as TIPT and files under Central Index Key 1393726. EDGAR puts it in the “Fire, Marine & Casualty Insurance” industry code with MD as its state or country of incorporation; its earlier registered name was TIPTREE FINANCIAL INC. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 4 filed 2026-10-07, across 1000 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-03-09 by TIPTREE INC. (CIK 1393726) — source document:

At Tiptree, our mission is to build long-term value by allocating capital to select small and middle market companies across industries. We have a significant track record investing in the insurance and credit-related financial sectors. With proprietary access and a flexible capital base, we seek to uncover compelling investment opportunities and support management teams in unlocking the full value potential of their businesses. This investment philosophy, executed by our experienced leadership, is our hallmark and has delivered consistent risk-adjusted returns to our stockholders since 2007. Our Operating Principles We acquire controlling interests and invest in businesses that we believe (i) operate in industries with long-term growth opportunities, (ii) have positive and stable cash flows, (iii) offer scalable business models with embedded optionality, and (iv) have strong management teams.

Financial trend for TIPTREE INC. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $1.40 billion (2022-12-31) to $488,000 (2025-12-31), a change of -100.0%; net income (loss) went from -$8.27 million (2022-12-31) to $34.93 million (2025-12-31), a change of +522.1%; total assets went from $4.04 billion (2022-12-31) to $6.84 billion (2025-12-31), a change of +69.3%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1393726, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures TIPTREE INC. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on TIPTREE INC. (CIK 1393726) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-07-29, and the most recent 10-K annual report was filed 2026-03-09. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 122 8-K or 6-K reports in TIPTREE INC.’s recent EDGAR index, the 4 listed here run from 2026-05-04 to 2026-07-29, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1393726 is on the EDGAR company page; the latest 10-K there is dated 2026-03-09 and the oldest filing in the recent index dates from 2015-05-15. Insider trades for TIPTREE INC. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Transcode therapeutics, inc. bullish and bearish analyst opinions

For “Transcode therapeutics, inc. bullish and bearish analyst opinions”, the matching SEC registrant is Transcode Therapeutics, Inc., which trades as RNAZ and files under Central Index Key 1829635. EDGAR puts it in the “Pharmaceutical Preparations” industry code with DE as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 8-K filed 2026-10-01, across 323 filings on record. This is reference material, not trading advice.

Financial trend for Transcode Therapeutics, Inc. from annual reports, periods 2022-12-31 to 2025-12-31: net income (loss) went from -$17.56 million (2022-12-31) to -$34.66 million (2025-12-31), a change of -97.3%; total assets went from $7.59 million (2022-12-31) to $162.40 million (2025-12-31), a change of +2040.2%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1829635, tags Assets, NetIncomeLoss; 4 periods shown, dashes mark figures Transcode Therapeutics, Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Transcode Therapeutics, Inc. (CIK 1829635) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2024-04-05, and the most recent 10-K annual report was filed 2026-04-15. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 82 8-K or 6-K reports in Transcode Therapeutics, Inc.’s recent EDGAR index, the 4 listed here run from 2026-08-03 to 2026-10-01, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 323 recent EDGAR filings, Transcode Therapeutics, Inc. most often filed 8-K (82), 4 (31), CORRESP (28), DEFA14A (19). A selection from 2026-08-05 to 2026-09-21:

The full record for CIK 1829635 is on the EDGAR company page; the latest 10-K/A there is dated 2026-04-30 and the oldest filing in the recent index dates from 2020-12-18. Insider trades for Transcode Therapeutics, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Treace medical concepts, inc. bullish and bearish analyst opinions

For “Treace medical concepts, inc. bullish and bearish analyst opinions”, the matching SEC registrant is TREACE MEDICAL CONCEPTS, INC., which trades as TMCI and files under Central Index Key 1630627. EDGAR puts it in the “Surgical & Medical Instruments & Apparatus” industry code with FL as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 4 filed 2026-10-02, across 442 filings on record. This is reference material, not trading advice.

Financial trend for TREACE MEDICAL CONCEPTS, INC. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $141.84 million (2022-12-31) to $212.69 million (2025-12-31), a change of +50.0%; net income (loss) went from -$42.81 million (2022-12-31) to -$59.00 million (2025-12-31), a change of -37.8%; total assets went from $159.02 million (2022-12-31) to $190.58 million (2025-12-31), a change of +19.8%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1630627, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures TREACE MEDICAL CONCEPTS, INC. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on TREACE MEDICAL CONCEPTS, INC. (CIK 1630627) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-07, and the most recent 10-K annual report was filed 2026-02-27. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 47 8-K or 6-K reports in TREACE MEDICAL CONCEPTS, INC.’s recent EDGAR index, the 4 listed here run from 2026-04-09 to 2026-08-07, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 442 recent EDGAR filings, TREACE MEDICAL CONCEPTS, INC. most often filed 4 (263), 8-K (47), 3 (22), 10-Q (17). A selection from 2026-08-12 to 2026-10-02:

The full record for CIK 1630627 is on the EDGAR company page; the latest 10-K there is dated 2026-02-27 and the oldest filing in the recent index dates from 2015-01-21. Insider trades for TREACE MEDICAL CONCEPTS, INC. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Trivago n.v. bullish and bearish analyst opinions

For “Trivago n.v. bullish and bearish analyst opinions”, the matching SEC registrant is trivago N.V., which trades as TRVG and files under Central Index Key 1683825. EDGAR puts it in the “Services-Computer Processing & Data Preparation” industry code with Netherlands as its state or country of incorporation; its earlier registered name was travel B.V.. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 4/A filed 2026-09-04, across 315 filings on record. This is reference material, not trading advice.

Financial trend for trivago N.V. from annual reports, periods 2022-12-31 to 2025-12-31: revenue was tagged only for 2022-12-31 at 535,004,000 EUR; net income (loss) went from -127,218,000 EUR (2022-12-31) to 11,220,000 EUR (2025-12-31), a change of +108.8%; total assets went from 691,592,000 EUR (2022-12-31) to 358,449,000 EUR (2025-12-31), a change of -48.2%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1683825, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures trivago N.V. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on trivago N.V. (CIK 1683825) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 20-F annual report was filed 2026-02-26. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 94 8-K or 6-K reports in trivago N.V.’s recent EDGAR index, the 4 listed here run from 2026-05-29 to 2026-08-04, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 315 recent EDGAR filings, trivago N.V. most often filed 6-K (94), 144 (42), SC 13G/A (35), SC 13D/A (28). A selection from 2026-08-18 to 2026-09-04:

The full record for CIK 1683825 is on the EDGAR company page; the latest 20-F there is dated 2026-02-26 and the oldest filing in the recent index dates from 2015-12-15. Insider trades for trivago N.V. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Trustmark corporation bullish and bearish analyst opinions

For “Trustmark corporation bullish and bearish analyst opinions”, the matching SEC registrant is TRUSTMARK CORP, which trades as TRMK and files under Central Index Key 36146. EDGAR puts it in the “National Commercial Banks” industry code with MS as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 8-K filed 2026-09-10, across 1002 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-02-23 by TRUSTMARK CORP (CIK 36146) — source document:

The Corporation Description of Business Trustmark Corporation (Trustmark), a Mississippi business corporation incorporated in 1968, is a bank holding company headquartered in Jackson, Mississippi. As previously disclosed, on August 4, 2025, Trustmark’s principal subsidiary, Trustmark National Bank, initially chartered by the State of Mississippi in 1889, converted from a national banking association to a Mississippi-chartered banking corporation and changed its name to Trustmark Bank (TB). TB is a member bank of the Federal Reserve System and is supervised by the Federal Reserve Bank of Atlanta (FRBA) and the Mississippi Department of Banking and Consumer Finance (MDBCF). At December 31, 2025, TB had total assets of $18.923 billion, which represented approximately 99.99% of the consolidated assets of Trustmark.

Financial trend for TRUSTMARK CORP from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $541.83 million (2022-12-31) to $948.62 million (2025-12-31), a change of +75.1%; net income (loss) went from $71.89 million (2022-12-31) to $224.13 million (2025-12-31), a change of +211.8%; total assets went from $18.02 billion (2022-12-31) to $18.93 billion (2025-12-31), a change of +5.0%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 36146, tags Assets, InterestAndDividendIncomeOperating, NetIncomeLoss; 4 periods shown, dashes mark figures TRUSTMARK CORP did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on TRUSTMARK CORP (CIK 36146) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-07-28, and the most recent 10-K annual report was filed 2026-02-23. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 112 8-K or 6-K reports in TRUSTMARK CORP’s recent EDGAR index, the 4 listed here run from 2026-04-29 to 2026-09-10, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 36146 is on the EDGAR company page; the latest 10-K there is dated 2026-02-23 and the oldest filing in the recent index dates from 2014-01-30. Insider trades for TRUSTMARK CORP appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Tucows inc. bullish and bearish analyst opinions

For “Tucows inc. bullish and bearish analyst opinions”, the matching SEC registrant is TUCOWS INC /PA/, which trades as TCX and files under Central Index Key 909494. EDGAR puts it in the “Services-Computer Processing & Data Preparation” industry code with PA as its state or country of incorporation; its earlier registered name was INFONAUTICS INC. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 8-K filed 2026-10-22, across 1000 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-03-12 by TUCOWS INC /PA/ (CIK 909494) — source document:

Our mission is to provide simple useful services that help people unlock the power of the Internet. We accomplish this by reducing the complexity of our customers’ experience as they access the Internet (at home or on the go) and while using Internet services such as domain name registration, email and other Internet related services. We are organized into three operating and reporting segments - Ting, Wavelo, and Tucows Domains. Each segment is differentiated primarily by their services, the markets they serve and the regulatory environments in which they operate. The Ting segment contains the operating results of our retail high speed Internet access operations, including its wholly owned subsidiaries - Cedar and Simply Bits.

Financial trend for TUCOWS INC /PA/ from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $321.14 million (2022-12-31) to $362.27 million (2024-12-31), a change of +12.8%; net income (loss) went from -$27.57 million (2022-12-31) to -$75.82 million (2025-12-31), a change of -175.0%; total assets went from $664.75 million (2022-12-31) to $730.91 million (2025-12-31), a change of +10.0%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 909494, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures TUCOWS INC /PA/ did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on TUCOWS INC /PA/ (CIK 909494) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-02-12, and the most recent 10-K annual report was filed 2026-03-12. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 136 8-K or 6-K reports in TUCOWS INC /PA/’s recent EDGAR index, the 4 listed here run from 2026-02-12 to 2026-10-22, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 909494 is on the EDGAR company page; the latest 10-K there is dated 2026-03-12 and the oldest filing in the recent index dates from 2010-08-09. Insider trades for TUCOWS INC /PA/ appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Txo partners, l.p. bullish and bearish analyst opinions

For “Txo partners, l.p. bullish and bearish analyst opinions”, the matching SEC registrant is TXO Partners, L.P., which trades as TXO and files under Central Index Key 1559432. EDGAR puts it in the “Crude Petroleum & Natural Gas” industry code with United States as its state or country of incorporation; its earlier registered name was TXO Energy Partners, L.P. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 4 filed 2026-08-13, across 201 filings on record. This is reference material, not trading advice.

Financial trend for TXO Partners, L.P. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $246.40 million (2022-12-31) to $401.01 million (2025-12-31), a change of +62.8%; net income (loss) went from -$7.67 million (2022-12-31) to -$21.62 million (2025-12-31), a change of -181.9%; total assets went from $924.63 million (2022-12-31) to $1.35 billion (2025-12-31), a change of +46.5%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1559432, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures TXO Partners, L.P. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on TXO Partners, L.P. (CIK 1559432) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 10-K annual report was filed 2026-02-26. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 32 8-K or 6-K reports in TXO Partners, L.P.’s recent EDGAR index, the 4 listed here run from 2026-03-10 to 2026-08-04, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 201 recent EDGAR filings, TXO Partners, L.P. most often filed 4 (73), 8-K (32), 3 (12), 10-Q (11). A selection from 2026-06-04 to 2026-08-13:

The full record for CIK 1559432 is on the EDGAR company page; the latest 10-K/A there is dated 2026-03-26 and the oldest filing in the recent index dates from 2012-10-04. Insider trades for TXO Partners, L.P. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Tyra biosciences

For “Tyra biosciences”, the matching SEC registrant is Tyra Biosciences, Inc., which trades as TYRA and files under Central Index Key 1863127. EDGAR puts it in the “Pharmaceutical Preparations” industry code with DE as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a SCHEDULE 13G filed 2026-09-21, across 425 filings on record. This is reference material, not trading advice.

Financial trend for Tyra Biosciences, Inc. from annual reports, periods 2022-12-31 to 2025-12-31: net income (loss) went from -$55.33 million (2022-12-31) to -$119.95 million (2025-12-31), a change of -116.8%; total assets went from $266.18 million (2022-12-31) to $282.61 million (2025-12-31), a change of +6.2%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1863127, tags Assets, NetIncomeLoss; 4 periods shown, dashes mark figures Tyra Biosciences, Inc. did not tag for that period.

Tyra Biosciences, Inc. has 425 filings in its recent EDGAR index, including 5 annual reports and 15 quarterly reports; its newest filing is a SCHEDULE 13G from 2026-09-21.

Current reports. Of the 46 8-K or 6-K reports in Tyra Biosciences, Inc.’s recent EDGAR index, the 4 listed here run from 2026-06-02 to 2026-09-15, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 425 recent EDGAR filings, Tyra Biosciences, Inc. most often filed 4 (171), 144 (49), 8-K (46), 3 (31). A selection from 2026-09-17 to 2026-09-21:

The full record for CIK 1863127 is on the EDGAR company page; the latest 10-K there is dated 2026-03-02 and the oldest filing in the recent index dates from 2021-05-28. Insider trades for Tyra Biosciences, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Valhi, inc. bullish and bearish analyst opinions

For “Valhi, inc. bullish and bearish analyst opinions”, the matching SEC registrant is VALHI INC /DE/, which trades as VHI and files under Central Index Key 59255. EDGAR puts it in the “Industrial Inorganic Chemicals” industry code with DE as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 8-K filed 2026-08-06, across 1000 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-03-10 by VALHI INC /DE/ (CIK 59255) — source document:

Valhi, Inc. (NYSE: VHI) is primarily a holding company. We operate through our wholly-owned and majority-owned subsidiaries, including NL Industries, Inc., Kronos Worldwide, Inc., CompX International Inc., Basic Management, Inc. and The LandWell Company. Kronos (NYSE: KRO), NL (NYSE: NL) and CompX (NYSE American: CIX) each file periodic reports with the U.S. Securities and Exchange Commission (SEC). Our principal executive offices are located at Three Lincoln Center 5430 LBJ Freeway, Suite 1700, Dallas, Texas 75240-2620. Our telephone number is (972) 233-1700. We maintain a website at www.valhi.net. Brief History LLC Corporation, our legal predecessor, was incorporated in Delaware in 1932. We are the successor company of the 1987 merger of LLC Corporation and another entity controlled by Contran Corporation.

Financial trend for VALHI INC /DE/ from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $2.22 billion (2022-12-31) to $2.08 billion (2025-12-31), a change of -6.5%; net income (loss) went from $87.20 million (2022-12-31) to -$57.60 million (2025-12-31), a change of -166.1%; total assets went from $2.84 billion (2022-12-31) to $2.63 billion (2025-12-31), a change of -7.2%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 59255, tags Assets, NetIncomeLoss, RevenueFromContractWithCustomerExcludingAssessedTax; 4 periods shown, dashes mark figures VALHI INC /DE/ did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on VALHI INC /DE/ (CIK 59255) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-06, and the most recent 10-K annual report was filed 2026-03-10. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 174 8-K or 6-K reports in VALHI INC /DE/’s recent EDGAR index, the 4 listed here run from 2026-05-07 to 2026-08-06, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 59255 is on the EDGAR company page; the latest 10-K there is dated 2026-03-10 and the oldest filing in the recent index dates from 2009-01-27. Insider trades for VALHI INC /DE/ appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Viomi technology co., ltd bullish and bearish analyst opinions

For “Viomi technology co., ltd bullish and bearish analyst opinions”, the matching SEC registrant is Viomi Technology Co., Ltd, which trades as VIOT and files under Central Index Key 1742770. EDGAR puts it in the “Household Appliances” industry code with Cayman Islands as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 4 filed 2026-10-09, across 139 filings on record. This is reference material, not trading advice.

Business description, quoted from the 20-F filed 2026-04-22 by Viomi Technology Co., Ltd (CIK 1742770) — source document:

As an industry-leading technology company in home water solutions in China, we have developed a distinctive “ Equipment + Consumables ” business model. To achieve this, we effect the 2024 reorganization transition by termination the contractual arrangements between Yunmi Hulian and Foshan Viomi, which has resulted in Foshan Viomi’s shareholder, Mr. Xiaoping Chen, fully controlling Foshan Viomi and its subsidiaries including Foshan Xiaoxian Hulian Electric Appliances Technology Co., Ltd., Foshan Qutansuo Electric Technology Co., Ltd., Guangdong AI Touch Technology Co., Ltd., and Zhuawa Technology (Guangdong) Co., Ltd. Additionally, Zhumeng Hulian and Guangdong Interconnect have enter into a new set of contractual arrangements, as a result of which the Company has controlled Guangdong Interconnect and consolidated its financial results.

Financial trend for Viomi Technology Co., Ltd from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from 1,790,245,000 CNY (2022-12-31) to 2,428,226,000 CNY (2025-12-31), a change of +35.6%; net income (loss) went from -275,515,000 CNY (2022-12-31) to -84,674,000 CNY (2023-12-31), a change of +69.3%; total assets went from 2,885,694,000 CNY (2022-12-31) to 2,390,948,000 CNY (2025-12-31), a change of -17.1%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1742770, tags Assets, NetIncomeLoss, RevenueFromContractWithCustomerExcludingAssessedTax; 4 periods shown, dashes mark figures Viomi Technology Co., Ltd did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Viomi Technology Co., Ltd (CIK 1742770) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 20-F annual report was filed 2026-04-22. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 53 8-K or 6-K reports in Viomi Technology Co., Ltd’s recent EDGAR index, the 4 listed here run from 2026-08-27 to 2026-10-09, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1742770 is on the EDGAR company page; the latest 20-F there is dated 2026-04-22 and the oldest filing in the recent index dates from 2018-06-26. Insider trades for Viomi Technology Co., Ltd appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Vox valor capital limited bullish and bearish analyst opinions

Read from its name, “Vox valor capital limited” is a a Commonwealth jurisdiction (most often Hong Kong, Australia, Singapore or Canada) entity — “Limited” is the company form used across Hong Kong, Australia, Singapore and other Commonwealth markets. Its accounts and exchange notices are published through that market’s exchange filing system (HKEXnews, ASX announcements, SGXNet or SEDAR+) (www.hkexnews.hk); the SEC only receives filings from such a company if it sells registered securities in the U.S.

No SEC filer could be matched to “Vox valor capital limited bullish and bearish analyst opinions” with a single, clear Central Index Key: neither EDGAR’s company index nor its full-text search (phrase “Vox valor capital limited”) returns a registrant with this name. Rather than show another company’s numbers, this section explains what the official record does and does not contain for the term “vox” (search terms considered: vox, valor, capital).

Even the shorter phrase “Vox valor capital” returns no EDGAR full-text hits, so no SEC filing since 2001 mentions it; the terms in this search (vox, valor, capital) point to a business outside the SEC system or one known by another legal name.

EDGAR’s company index has 15 entities whose registered name contains the word “vox”; the first few are shown below so you can see whether any is the business you mean. None of them matches the full search wording closely enough to be treated as the same company.

Word by word, the number of EDGAR registrant names containing each term of this search is: “vox” 15, “valor” 208, “capital” 482. A term that appears in many unrelated names is a weak identifier on its own, which is why this page does not attach any one filer’s financial data to the query.

Sample EDGAR registrant names, term by term — containing “vox”: HUDSON VOX LLC (CIK 2106614), PT VOX INOVASI NUSANTARA (CIK 2148728), SILICON VOX CORP (CIK 1466367); containing “valor”: 4TH SOUTH VALOR CAPITAL LLC (CIK 2046396), ALFA VALOR INVESTMENTS LTD (CIK 2080565), BIP VALOR FUND 3-AI, LLC (CIK 1973688); containing “capital”: &AFFILIATES CAPITAL LLC (CIK 2124638), 021T CAPITAL FUND I, L.P. (CIK 2109188), 021T CAPITAL SPV ORNN, L.P. (CIK 2158838). These are listed only to show how the individual words map onto unrelated filers; none should be read as the subject of the search.

For this particular search: analyst views on “vox” are third-party opinions; the SEC neither issues nor reviews ratings, so check any rating against the company’s own annual report. If the business says it is registered but does not appear in EDGAR or on FINRA BrokerCheck, treat that as a red flag. This page offers no buy or sell recommendation.

Updated Oct 25, 2026 ET

W&t offshore sec filing october 2026

For “W&t offshore sec filing october 2026”, the matching SEC registrant is W&T OFFSHORE INC, which trades as WTI and files under Central Index Key 1288403. EDGAR puts it in the “Crude Petroleum & Natural Gas” industry code with TX as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 8-K filed 2026-10-07, across 1000 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-03-16 by W&T OFFSHORE INC (CIK 1288403) — source document:

W&T Offshore, Inc. (“we,” “our” or “us”) is a publicly held Texas corporation. We are an independent oil and natural gas producer with substantially all our operations offshore in the Gulf of America. We are active in the acquisition, exploration and development of oil and natural gas properties. We operate in one reportable segment. Since our founding in 1983 by our Chairman and Chief Executive Officer, Tracy Krohn, we have developed significant technical expertise in finding and developing properties in the Gulf of America with existing production which provide the best opportunity to achieve a return on our invested capital. We have successfully discovered and produced properties on the conventional shelf and in the deepwater across the Gulf of America.

Financial trend for W&T OFFSHORE INC from annual reports, periods 2022-12-31 to 2025-12-31: net income (loss) went from $231.15 million (2022-12-31) to -$150.06 million (2025-12-31), a change of -164.9%; total assets went from $1.43 billion (2022-12-31) to $955.81 million (2025-12-31), a change of -33.2%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1288403, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures W&T OFFSHORE INC did not tag for that period.

W&T OFFSHORE INC has 1000 filings in its recent EDGAR index, including 20 annual reports and 60 quarterly reports; its newest filing is a 8-K from 2026-10-07.

Current reports. Of the 242 8-K or 6-K reports in W&T OFFSHORE INC’s recent EDGAR index, the 4 listed here run from 2026-06-04 to 2026-10-07, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1288403 is on the EDGAR company page; the latest 10-K there is dated 2026-03-16 and the oldest filing in the recent index dates from 2006-09-01. Insider trades for W&T OFFSHORE INC appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Wellchange holdings company limited bullish and bearish analyst opinions

For “Wellchange holdings company limited bullish and bearish analyst opinions”, the matching SEC registrant is Wellchange Holdings Co Ltd, which trades as WCT and files under Central Index Key 1990251. EDGAR puts it in the “Services-Prepackaged Software” industry code with an unstated jurisdiction as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 6-K filed 2026-10-13, across 85 filings on record. This is reference material, not trading advice.

Financial trend for Wellchange Holdings Co Ltd from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $1.67 million (2022-12-31) to $1.35 million (2025-12-31), a change of -19.3%; net income (loss) went from $780,648 (2022-12-31) to -$7.32 million (2025-12-31), a change of -1038.0%; total assets went from $3.30 million (2023-12-31) to $13.62 million (2025-12-31), a change of +313.0%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1990251, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures Wellchange Holdings Co Ltd did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Wellchange Holdings Co Ltd (CIK 1990251) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 20-F annual report was filed 2026-05-14. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 35 8-K or 6-K reports in Wellchange Holdings Co Ltd’s recent EDGAR index, the 4 listed here run from 2026-08-31 to 2026-10-13, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 85 recent EDGAR filings, Wellchange Holdings Co Ltd most often filed 6-K (35), CORRESP (7), EFFECT (5), F-1 (4). A selection from 2026-07-07 to 2026-08-28:

The full record for CIK 1990251 is on the EDGAR company page; the latest 20-F there is dated 2026-05-14 and the oldest filing in the recent index dates from 2023-09-28. Insider trades for Wellchange Holdings Co Ltd appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Xilio therapeutics, inc. bullish and bearish analyst opinions

For “Xilio therapeutics, inc. bullish and bearish analyst opinions”, the matching SEC registrant is Xilio Therapeutics, Inc., which trades as XLO and files under Central Index Key 1840233. EDGAR puts it in the “Pharmaceutical Preparations” industry code with DE as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 4 filed 2026-10-02 (this view begins at filings dated on or before 2026-06-12), across 357 filings on record. This is reference material, not trading advice.

Financial trend for Xilio Therapeutics, Inc. from quarterly and annual reports (three-month periods), periods 2025-09-30 to 2026-06-30: revenue went from $19.07 million (2025-09-30) to $18.69 million (2026-06-30), a change of -2.0%; net income (loss) went from -$16.29 million (2025-09-30) to -$6.37 million (2026-06-30), a change of +60.9%; total assets went from $133.69 million (2025-09-30) to $154.25 million (2026-06-30), a change of +15.4%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1840233, tags Assets, NetIncomeLoss, RevenueFromContractWithCustomerExcludingAssessedTax; 3 periods shown, dashes mark figures Xilio Therapeutics, Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Xilio Therapeutics, Inc. (CIK 1840233) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-12, and the most recent 10-K annual report was filed 2026-03-23. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 65 8-K or 6-K reports in Xilio Therapeutics, Inc.’s recent EDGAR index, the 4 listed here run from 2026-02-24 to 2026-03-23, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 357 recent EDGAR filings, Xilio Therapeutics, Inc. most often filed 4 (106), 8-K (65), 3 (40), 10-Q (15). A selection from 2026-06-12 to 2026-06-12:

The full record for CIK 1840233 is on the EDGAR company page; the latest 10-K there is dated 2026-03-23 and the oldest filing in the recent index dates from 2021-01-21. One example from this record is the 10-Q filed 2026-08-12 (document). Insider trades for Xilio Therapeutics, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Xpon technologies group limited bullish and bearish analyst opinions

“Limited” is the company form used across Hong Kong, Australia, Singapore and other Commonwealth markets. The name “Xpon technologies group limited” therefore points to a company organised in a Commonwealth jurisdiction (most often Hong Kong, Australia, Singapore or Canada), and its official disclosures are on that market’s exchange filing system (HKEXnews, ASX announcements, SGXNet or SEDAR+) (www.hkexnews.hk), not on EDGAR.

No SEC filer could be matched to “Xpon technologies group limited bullish and bearish analyst opinions” with a single, clear Central Index Key: neither EDGAR’s company index nor its full-text search (phrase “Xpon technologies group limited”) returns a registrant with this name. Rather than show another company’s numbers, this section explains what the official record does and does not contain for the term “xpon” (search terms considered: xpon, technologies).

Even the shorter phrase “Xpon technologies group” returns no EDGAR full-text hits, so no SEC filing since 2001 mentions it; the terms in this search (xpon, technologies) point to a business outside the SEC system or one known by another legal name.

EDGAR’s company index has 0 entities whose registered name contains the word “xpon”, so the business is most likely not registered with the SEC under that name.

Word by word, the number of EDGAR registrant names containing each term of this search is: “xpon” 0, “technologies” 474. A term that appears in many unrelated names is a weak identifier on its own, which is why this page does not attach any one filer’s financial data to the query.

Sample EDGAR registrant names, term by term — containing “technologies”: 1 FINAX AI TECHNOLOGIES, INC (CIK 2122965), 1 LANE TECHNOLOGIES CORP (CIK 1422222), 10C TECHNOLOGIES INC (CIK 1405978). These are listed only to show how the individual words map onto unrelated filers; none should be read as the subject of the search.

For this particular search: analyst views on “xpon” are third-party opinions; the SEC neither issues nor reviews ratings, so check any rating against the company’s own annual report. If the business says it is registered but does not appear in EDGAR or on FINRA BrokerCheck, treat that as a red flag. This page offers no buy or sell recommendation.

Updated Oct 25, 2026 ET

Yarrow bioscience inc bullish and bearish analyst opinions

For “Yarrow bioscience inc bullish and bearish analyst opinions”, the matching SEC registrant is Yarrow Bioscience, Inc., which trades as YARW and files under Central Index Key 1566044. EDGAR puts it in the “Pharmaceutical Preparations” industry code with DE as its state or country of incorporation; its earlier registered name was VYNE Therapeutics Inc. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a SCHEDULE 13G filed 2026-10-07, across 677 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-02-27 by Yarrow Bioscience, Inc. (CIK 1566044) — source document:

We are a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat inflammatory and immune-mediated conditions with high unmet need. We have exclusive worldwide rights to research, develop and commercialize products containing small molecule bromodomain and extra-terminal domain (“BET”) inhibitors for the treatment of any disease, disorder or condition in humans, which we licensed from Tay Therapeutics Ltd., formerly known as In4Derm Ltd ("Tay"). BET proteins are epigenetic enablers of transcription that regulate the expression of specific genes. Each BET protein consists of two bromodomains (“BD1” and “BD2”) and one end terminal (“ET”) domain. Through our transaction with Tay, we obtained access to a library of new small molecule BET inhibitor compounds including those that inhibit both BD1 and BD2 (“pan-BD” BET inhibitor) and that selectively inhibit BD2 (“BD2-selective” BET inhibitor).

Financial trend for Yarrow Bioscience, Inc. from annual reports, periods 2022-12-31 to 2025-12-31: net income (loss) went from -$23.21 million (2022-12-31) to -$26.48 million (2025-12-31), a change of -14.1%; total assets went from $40.76 million (2022-12-31) to $30.16 million (2025-12-31), a change of -26.0%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1566044, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures Yarrow Bioscience, Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Yarrow Bioscience, Inc. (CIK 1566044) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-07-28, and the most recent 10-K annual report was filed 2026-02-27. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 130 8-K or 6-K reports in Yarrow Bioscience, Inc.’s recent EDGAR index, the 4 listed here run from 2026-07-28 to 2026-09-14, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1566044 is on the EDGAR company page; the latest 10-K there is dated 2026-02-27 and the oldest filing in the recent index dates from 2013-01-07. Insider trades for Yarrow Bioscience, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Yd electronic technology co.,ltd. bullish and bearish analyst opinions

Read from its name, “Yd electronic technology co.,ltd.” is a China, Taiwan, Korea or Japan entity — “Co., Ltd.” is the English rendering used by limited companies across East Asia. Its accounts and exchange notices are published through the home-exchange disclosure system (SSE/SZSE in mainland China, MOPS in Taiwan, DART in Korea, EDINET in Japan) (mops.twse.com.tw); the SEC only receives filings from such a company if it sells registered securities in the U.S.

No SEC filer could be matched to “Yd electronic technology co.,ltd. bullish and bearish analyst opinions” with a single, clear Central Index Key: the phrase “Yd electronic technology co.,ltd.” appears in 532+ EDGAR full-text search results, but those hits do not point to one clearly identifiable issuer with its own CIK. Rather than show another company’s numbers, this section explains what the official record does and does not contain for the term “electronic” (search terms considered: electronic, technology).

A broader EDGAR full-text search for the shorter phrase “Yd electronic technology” finds 532+ filing documents; among the top 100, the filers mentioning it most are DFA INVESTMENT TRUST CO (CIK 0000896162) (69); DFA INVESTMENT DIMENSIONS GROUP INC (CIK 0000355437) (16); Dimensional ETF Trust (CIK 0001816125) (10). Those are documents that name the term, not proof that any of these filers is the business in the search.

In the 100 most relevant full-text hits returned for “Yd electronic technology co.,ltd.”, filings range from 2025-03-26 to 2026-09-24. The filers whose documents mention it most often are DFA INVESTMENT TRUST CO (CIK 0000896162) (69 hits); DFA INVESTMENT DIMENSIONS GROUP INC (CIK 0000355437) (16 hits); Dimensional ETF Trust (CIK 0001816125) (10 hits); SPDR INDEX SHARES FUNDS (CIK 0001168164) (5 hits). A mention in another company’s filing — as a customer, supplier, lender, fund holding or deal counterparty — does not make that filer the company you searched for.

Word by word, the number of EDGAR registrant names containing each term of this search is: “electronic” 135, “technology” 485. A term that appears in many unrelated names is a weak identifier on its own, which is why this page does not attach any one filer’s financial data to the query.

Updated Oct 25, 2026 ET

Yung zip chemical ind. co., ltd. bullish and bearish analyst opinions

“Co., Ltd.” is the English rendering used by limited companies across East Asia. The name “Yung zip chemical ind. co., ltd.” therefore points to a company organised in China, Taiwan, Korea or Japan, and its official disclosures are on the home-exchange disclosure system (SSE/SZSE in mainland China, MOPS in Taiwan, DART in Korea, EDINET in Japan) (mops.twse.com.tw), not on EDGAR.

No SEC filer could be matched to “Yung zip chemical ind. co., ltd. bullish and bearish analyst opinions” with a single, clear Central Index Key: neither EDGAR’s company index nor its full-text search (phrase “Yung zip chemical ind. co., ltd.”) returns a registrant with this name. Rather than show another company’s numbers, this section explains what the official record does and does not contain for the term “yung” (search terms considered: yung, zip, chemical, ind).

Even the shorter phrase “Yung zip chemical” returns no EDGAR full-text hits, so no SEC filing since 2001 mentions it; the terms in this search (yung, zip, chemical, ind) point to a business outside the SEC system or one known by another legal name.

EDGAR’s company index has 47 entities whose registered name contains the word “yung”; the first few are shown below so you can see whether any is the business you mean. None of them matches the full search wording closely enough to be treated as the same company.

Word by word, the number of EDGAR registrant names containing each term of this search is: “yung” 47, “zip” 28, “chemical” 227, “ind” 112. A term that appears in many unrelated names is a weak identifier on its own, which is why this page does not attach any one filer’s financial data to the query.

Sample EDGAR registrant names, term by term — containing “yung”: CHANG YUNG-HSI (CIK 2062400), CHEN JUI-YUNG (CIK 1359210), CHEN TIMOTHY YUNG-CHENG (CIK 1374068); containing “zip”: 09 CITY ZIP/CAPOTE'S TUNE, LLC (CIK 1503690), 13 CITY ZIP/TIZADO, LLC (CIK 1640532), 15 CITY ZIP/WALLINGFORD, LLC (CIK 1682904); containing “chemical”: AFTON CHEMICAL ASIA PACIFIC LLC (CIK 1389329), AFTON CHEMICAL CANADA HOLDINGS, INC. (CIK 1389328), AFTON CHEMICAL CORP (CIK 1237227); containing “ind”: 3645 PEACHTREE IND CW LLC (CIK 2124112), ACOF VI (IND) FEEDER, L.P. (CIK 1831772), ALLEN TESTING CO /IND (CIK 849486). These are listed only to show how the individual words map onto unrelated filers; none should be read as the subject of the search.

For this particular search: analyst views on “yung” are third-party opinions; the SEC neither issues nor reviews ratings, so check any rating against the company’s own annual report. If the business says it is registered but does not appear in EDGAR or on FINRA BrokerCheck, treat that as a red flag. This page offers no buy or sell recommendation.

Updated Oct 25, 2026 ET

Zevia pbc bullish and bearish analyst opinions

For “Zevia pbc bullish and bearish analyst opinions”, the matching SEC registrant is Zevia PBC, which trades as ZVIA and files under Central Index Key 1854139. EDGAR puts it in the “Bottled & Canned Soft Drinks & Carbonated Waters” industry code with DE as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 8-K filed 2026-10-23, across 357 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-02-25 by Zevia PBC (CIK 1854139) — source document:

Zevia PBC (“Zevia PBC”) was incorporated as a Delaware public benefit corporation on March 23, 2021, and prior to the consummation of the reorganization and initial public offering (“IPO”), did not conduct any activities other than those incidental to our formation and the IPO. In connection with the completion of the IPO on July 26, 2021, Zevia PBC became a holding company, and its sole material asset is a controlling equity interest in Zevia LLC, a Delaware limited liability company (“Zevia LLC”). As the sole managing member of Zevia LLC, Zevia PBC operates and controls all of the business and affairs of Zevia LLC and, through Zevia LLC, conducts its business.

Financial trend for Zevia PBC from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $163.18 million (2022-12-31) to $161.26 million (2025-12-31), a change of -1.2%; net income (loss) went from -$47.65 million (2022-12-31) to -$9.92 million (2025-12-31), a change of +79.2%; total assets went from $98.93 million (2022-12-31) to $63.62 million (2025-12-31), a change of -35.7%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1854139, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures Zevia PBC did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Zevia PBC (CIK 1854139) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-05, and the most recent 10-K annual report was filed 2026-02-25. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 50 8-K or 6-K reports in Zevia PBC’s recent EDGAR index, the 4 listed here run from 2026-06-15 to 2026-10-23, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1854139 is on the EDGAR company page; the latest 10-K there is dated 2026-02-25 and the oldest filing in the recent index dates from 2021-04-19. Insider trades for Zevia PBC appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Zhengye biotechnology holding limited bullish and bearish analyst opinions

For “Zhengye biotechnology holding limited bullish and bearish analyst opinions”, the matching SEC registrant is Zhengye Biotechnology Holding Ltd, which trades as ZYBT and files under Central Index Key 1975641. EDGAR puts it in the “Pharmaceutical Preparations” industry code with China as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 6-K filed 2026-08-06, across 61 filings on record. This is reference material, not trading advice.

See “Risk Factors — Risks Relating to Doing Business in China — Chinese regulatory authorities could disallow our holding company structure, which may result in a material change in the operating entity’s operations and/or a material change in the value of the securities we are registering for sale, including that it could cause the value of such securities to significantly decline or become worthless.” Completion of the Initial Public Offering (“IPO”) In January 2025, we closed our IPO of 1,500,000 ordinary shares at the public offering price of $4.00 per share, and Kingswood Capital Partners, LLC, as the representative of the underwriters of the IPO, exercised its over-allotment option in full to purchase an additional 225,000 ordinary shares of the Company at a public offering price of $4.00 per share.

Analyst ratings, price targets and “bullish” or “bearish” calls on Zhengye Biotechnology Holding Ltd (CIK 1975641) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 20-F annual report was filed 2026-04-28. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Updated Oct 25, 2026 ET

(serve robotics inc. or serv or nano dimension ltd. or nndm or nauticus robotics, inc. or kitt) and (latest news or contracts or earnings guidance)

A Boolean robotics query on Serve Robotics, Nano Dimension and Nauticus Robotics, without Symbotic. Filing records below were read from EDGAR on Oct 25, 2026, one registrant per row.

Serve Robotics Inc. /DE/ (SERV; general industrial machinery & equipment, nec, incorporated in DE) — recent current reports: the 8-K of 2026-08-06 covering 2.02 (results of operations and financial condition), 7.01 (regulation fd disclosure), 9.01 (financial statements and exhibits); the 8-K of 2026-06-24 covering 5.02 (departure/election of directors or officers), 9.01 (financial statements and exhibits). Year to 2022-12-31: revenue of $107,819, net income (loss) -$21.86 million (10-K, 2024-02-29).

Nano Dimension Ltd. (NNDM; printed circuit boards, incorporated in Israel) — recent current reports: the 8-K of 2026-08-06 covering 2.02 (results of operations and financial condition), 9.01 (financial statements and exhibits); the 8-K of 2026-07-21 covering 1.01 (entry into a material definitive agreement), 5.01 (changes in control of registrant), 5.02 (departure/election of directors or officers), 5.07 (submission of matters to a vote of security holders), 8.01 (other events), 9.01 (financial statements and exhibits). Year to 2024-12-31: revenue of $57.77 million, net income (loss) -$98.83 million (10-K, 2026-03-31).

Nauticus Robotics, Inc. (KITT; general industrial machinery & equipment, nec, incorporated in DE) filed the 8-K of 2026-10-01 covering 1.01 (entry into a material definitive agreement), 9.01 (financial statements and exhibits); the 8-K of 2026-09-29 covering 1.01 (entry into a material definitive agreement), 9.01 (financial statements and exhibits). Year to 2021-12-31: FY revenue tagged at $8.59 million, profit or loss -$15.13 million (10-K, 2023-03-28).

How often each filed an 8-K under Item 1.01, entry into a material definitive agreement — the item a significant partnership or contract would be filed under: SERV 12 (latest 2026-01-21), NNDM 2 (latest 2026-07-21), KITT 33 (latest 2026-10-02).

Leaving Symbotic out changes the character of this basket: the three remaining names are all small-capitalisation companies with net losses, so contract wins disclosed under 8-K Item 1.01 or Item 8.01 tend to move their shares more than they would a larger warehouse-automation supplier. Guidance, where given, is usually furnished with the earnings release under Item 2.02 rather than in the 10-Q itself.

Aerovironment sec filing october 2026 avav

For “Aerovironment sec filing october 2026 avav”, the matching SEC registrant is AeroVironment Inc, which trades as AVAV and files under Central Index Key 1368622. EDGAR puts it in the “Aircraft” industry code with DE as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 144 filed 2026-10-15, across 1002 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-06-29 by AeroVironment Inc (CIK 1368622) — source document:

We develop and deploy autonomous systems, precision strike systems, counter-UAS technologies, space-based platforms, directed energy systems, and cyber and electronic warfare capabilities. We operate an international manufacturing footprint, delivering proven systems and capabilities in markets that we believe offer the potential for significant long-term growth. In addition, we believe that some of the innovative potential products, services and technologies in our R&D pipeline will emerge as new growth platforms in the future, creating additional market opportunities. Effective May 1, 2025 in connection with our acquisition of BlueHalo Financing Topco, LLC (“BlueHalo”), we operate our business in two reportable segments: (1) Autonomous Systems (“AxS”) and (2) Space, Cyber and Directed Energy (“SCDE”). ​ Autonomous Systems ​ Uncrewed Aircraft Systems (“UAS").

Financial trend for AeroVironment Inc from annual reports, periods 2023-04-30 to 2026-04-30: net income (loss) went from -$176.17 million (2023-04-30) to -$265.12 million (2026-04-30), a change of -50.5%; total assets went from $824.58 million (2023-04-30) to $5.72 billion (2026-04-30), a change of +593.3%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1368622, tags Assets, ProfitLoss, Revenues; 4 periods shown, dashes mark figures AeroVironment Inc did not tag for that period.

AeroVironment Inc has 1002 filings in its recent EDGAR index, including 14 annual reports and 40 quarterly reports; its newest filing is a 144 from 2026-10-15.

Current reports. Of the 171 8-K or 6-K reports in AeroVironment Inc’s recent EDGAR index, the 4 listed here run from 2026-07-29 to 2026-09-30, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1368622 is on the EDGAR company page; the latest 10-K there is dated 2026-06-29 and the oldest filing in the recent index dates from 2013-04-26. Insider trades for AeroVironment Inc appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Aisp airship ai sec filing october 2026

For “Aisp airship ai sec filing october 2026”, the matching SEC registrant is Airship AI Holdings, Inc., which trades as AISP, AISPW and files under Central Index Key 1842566. EDGAR puts it in the “Services-Prepackaged Software” industry code with DE as its state or country of incorporation; its earlier registered name was BYTE Acquisition Corp. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a PRE 14A filed 2026-10-19 (this view begins at filings dated on or before 2026-02-27), across 324 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-02-17 by Airship AI Holdings, Inc. (CIK 1842566) (passage 3, continuing from the earlier excerpt) — source document:

Financial trend for Airship AI Holdings, Inc. from annual reports, periods 2021-12-31 to 2022-12-31: revenue was tagged only for 2022-12-31 at $14.55 million; net income (loss) went from $5.02 million (2021-12-31) to -$487,493 (2022-12-31), a change of -109.7%; total assets went from $326.07 million (2021-12-31) to $3.91 million (2022-12-31), a change of -98.8%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1842566, tags Assets, NetIncomeLoss, Revenues; 2 periods shown, dashes mark figures Airship AI Holdings, Inc. did not tag for that period.

Current reports. Of the 50 8-K or 6-K reports in Airship AI Holdings, Inc.’s recent EDGAR index, the 4 listed here run from 2024-12-31 to 2025-05-15, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1842566 is on the EDGAR company page; the latest 10-K there is dated 2026-02-17 and the oldest filing in the recent index dates from 2021-02-03. One example from this record is the S-3/A filed 2026-05-14 (document). Insider trades for Airship AI Holdings, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Albemarle tesla plug power intel strategic collaboration

The “strategic collaboration” wording of the Albemarle, Tesla, Plug Power and Intel search. Each company named is a separate SEC registrant reporting on its own; filing data as of Oct 25, 2026.

PLUG POWER INC (PLUG; electrical industrial apparatus) — EDGAR lists the 8-K of 2025-12-05 covering 8.01 (other events); the 8-K of 2025-11-21 covering 1.01 (entry into a material definitive agreement), 1.02 (termination of a material definitive agreement), 2.03 (creation of a direct financial obligation), 3.02 (unregistered sales of equity securities), 8.01 (other events), 9.01 (financial statements and exhibits). Year to 2017-12-31: annual sales of $100.15 million, net result -$127.08 million (10-K, 2020-03-10).

ALBEMARLE CORP (ALB; plastic materials, synth resins & nonvulcan elastomers) filed the 8-K of 2025-08-04 covering 5.02 (departure/election of directors or officers); the 8-K of 2025-07-30 covering 2.02 (results of operations and financial condition), 9.01 (financial statements and exhibits). Year to 2017-12-31: FY revenue tagged at $3.07 billion, profit or loss $54.85 million (10-K, 2020-02-26).

Tesla, Inc. (TSLA; motor vehicles & passenger car bodies) filed the 8-K of 2025-07-02 covering 2.02 (results of operations and financial condition), 9.01 (financial statements and exhibits); the 8-K of 2025-05-16 covering 5.03 (amendments to articles of incorporation or bylaws), 9.01 (financial statements and exhibits). Year to 2017-12-31: FY revenue tagged at $11.76 billion, profit or loss -$1.96 billion (10-K, 2020-02-13).

INTEL CORP (INTC; semiconductors & related devices) — EDGAR lists the 8-K of 2025-09-15 covering 2.01 (completion of acquisition or disposition of assets), 7.01 (regulation fd disclosure), 9.01 (financial statements and exhibits); the 8-K of 2025-09-08 covering 5.02 (departure/election of directors or officers), 9.01 (financial statements and exhibits). Year to 2017-12-30: annual sales of $62.76 billion, net result $9.60 billion (10-K, 2020-01-24).

Item 1.01 count (entry into a material definitive agreement — the item a significant partnership or contract would be filed under): PLUG 39 (latest 2026-07-13), ALB 18 (latest 2026-03-25), TSLA 19 (latest 2026-09-29), INTC 9 (latest 2025-08-29).

Updated Oct 25, 2026 ET

Allogene therapeutics

For “Allogene therapeutics”, the matching SEC registrant is Allogene Therapeutics, Inc., which trades as ALLO and files under Central Index Key 1737287. EDGAR puts it in the “Biological Products, (No Diagnostic Substances)” industry code with an unstated jurisdiction as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 4 filed 2026-10-23, across 583 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-03-12 by Allogene Therapeutics, Inc. (CIK 1737287) — source document:

We are a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. We are developing a pipeline of “off-the-shelf” T cell product candidates that are designed to target and kill cancer cells in patients or eliminate pathogenic autoreactive cells in patients with autoimmune disorders. Our engineered T cells are allogeneic, meaning they are derived from healthy donors for intended use in any patient, rather than from an individual patient for that patient’s use, as in the case of autologous T cells. We believe this key difference will enable us to deliver readily available treatments faster, more reliably, at greater scale, and to more patients.

Financial trend for Allogene Therapeutics, Inc. from annual reports, periods 2023-09-30 to 2025-12-31: revenue went from $95,000 (2023-12-31) to $0 (2025-12-31), a change of -100.0%; net income (loss) went from -$327.26 million (2023-12-31) to -$190.89 million (2025-12-31), a change of +41.7%; total assets went from $713.41 million (2023-09-30) to $415.90 million (2025-12-31), a change of -41.7%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1737287, tags Assets, NetIncomeLoss, RevenueFromContractWithCustomerExcludingAssessedTax; 4 periods shown, dashes mark figures Allogene Therapeutics, Inc. did not tag for that period.

Allogene Therapeutics, Inc. has 583 filings in its recent EDGAR index, including 8 annual reports and 24 quarterly reports; its newest filing is a 4 from 2026-10-23.

Current reports. Of the 84 8-K or 6-K reports in Allogene Therapeutics, Inc.’s recent EDGAR index, the 4 listed here run from 2026-05-28 to 2026-09-02, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1737287 is on the EDGAR company page; the latest 10-K there is dated 2026-03-12 and the oldest filing in the recent index dates from 2018-04-19. Insider trades for Allogene Therapeutics, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET